Zydus Cadila receives nod to market anti-cancer medicine

The global pharmaceutical company, Zydus Cadila announced on Thursday that it has received tentative approval from United States Food & Drug Administration (USFDA) to market anti-cancer medicine.

Zydus Cadila is said to market Palbociclib capsules (US RLD: Ibrance capsules) in the strengths of 75 mg, 100 mg, and 125 mg. The drug interferes with the growth and spread of cancer cells in the body.

The manufacturing of the drug will take place at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

Zydus Cadila has filed more than 390 abbreviated new drug applications (ANDAs) so far and currently has 302 approvals. The company is one of the leading players that cater to different therapeutic areas such as cardiovascular, gastrointestinal, respiratory, pain management, and so on.

At 2.41 pm today, its share was trading 1.42 per cent down at Rs 378.1 on BSE. The share has a 52-week high of Rs 422.8 and a 52-week low of Rs 212.7 on BSE.